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ABSTRACT
Background and the purpose of the study: Amphotericin B (AmB) which is an appropriate 
antibiotic for the treatment of mycosis has many toxic effects including nephrotoxicity. Recently 
preparation of a new drug loaded nanoparticles  for the reduction of toxicity and increase in 
the effectiveness of AmB has been reported. The objective of this study was to prepare and 
evaluate in vitro and in vivo efficacy of the spray-dried AmB-loaded nanospheres. 
Methods:  AmB-loaded nanospheres was prepared by means of nanoprecipitation method. 
The spray-dried nanospheres was prepared by using aerosil and AmB entrapment efficacy 
was measured by HPLC method. Minimum inhibitory concentration (MIC) of AmB-loaded 
nanospheres against  Candida albicans (ATCC 90028) was determined by using microdilution 
method and its in vitro haemolytic effect and antifungal efficacy on infected rabbits was also 
analyzed.
Results: The entrapment efficacy for AmB loaded nanospheres was 65.2% ± 3.  The MIC 
of AmB-loaded nanospheres against C. albicans compared to the free antibiotic was lower 
significantly. Also, the AmB-loaded nanospheres found to be 9.5 times less toxic than free 
AmB on human red blood cells. In vivo testing indicated that AmB-loaded nanospheres have a 
stronger protective effect against candidiasis compared to the free AmB.   
Conclusion: Results of this study suggest that prepared spray-dried AmB-loaded nanospheres 
would be a good choice for the treatment of mycosis because of low toxicity and high stability 
and effectiveness.
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INTRODUCTION
Amphotericin B (AmB) is a suitable antibiotic 
for the treatment of systemic mycosis (1). 
However, this drug has low aqeous solibility and 
is poorly absorbed in gastro-intestinal tract which 
limit its uses for the treatment of systemic fungal 
infections (2, 3). In recent years, various types 
of drug formulations for AmB such as micellar 
solution of AmB with deoxycholate having serious 
nephrotoxicity and lipid-based nanoparticulate 
formulations of low nephrotoxicity have been 
investigated (4, 5). In addition these formulations 
are  quite  expensive.  In  this  field  polymeric 
nanoparticle delivery systems has been 
extensively investigated (6, 7). Nanoparticles, as 
a polymeric sub micron carriers have a general 
name to describe nanocapsules and nanospheres 
(8). According to the literature, the nanospheres 
have a polymeric wall envelope and an oil core 
matrix (9). Nanosphere suspensions have been 
developed as drug targeting delivery system, 
using polyesters, poly (alklylcyanoacrylate), 
poly (lactic acid) and other polymers (10, 11). 
The development of these systems for industrial 
objectives are limited due to low maintaining 
stability of suspensions for a prolonged time 
period and usually, prepared nanoparticles tend 
to aggregate because nanoparticles sediment 
slowly and seperated by severe mixing (12, 
13). However, aggregation of nanoparticles 
in suspension can occur (4). Spray-drying has 
been shown as a good method for drying of 
nanoparticles and to increase the stability of 
drug-loaded nanoparticles (8, 13). The aim of 
the present study was to apply the spray-dried 
technique for drying of the prepared AmB-loaded 
nanospheres using poly[(±)-lactid-co-glycolid] 
(PLGA) and evaluation of the stability and in 
vitro hemolytic effect and in vivo  therapeutic 
efficacy of the prepared nanoparticles.
351Amphotericin B-loaded nanospheres 352
MATERIAL AND METHODS
PLGA (Capped, alkylester terminated, M.W.: 76000-
115000 and Ratio of lactid to glycolid of 75:25), 
sorbitan monostearate, RPMI 1640 and AmB were 
obtained from Sigma (St. Louis, USA). Colloidal 
silicon dioxide (aerosil 200) was purchased from 
Degussa (Frankfurt, Germany).
Preparation of the spray-dried AmB-loaded 
nanospheres 
All samples were prepared by nanoprecipitation 
of PLGA by the reported method (14). Briefly, the 
AmB-loaded nanosphers suspension was prepared 
by dissolving the PLGA (l g), AmB (0.150 g) and 
the sorbitan monostearate (0.766 g) in acetone (270 
ml) and polysorbate 80 (0.766 g). Then, the prepared 
suspension was spray-dried by the reported method 
(13). In brief, aerosil 200 [3.0% (w/v)] was added 
to the nanospheres suspension and the mixture was 
fed into a mini-spray-dryer Büchi MSD 190 (Flawil, 
Switzerland). 
In vitro dissolution studies
AmB-loaded nanospheres containing 30 µg of AmB 
were placed into 20 ml of the dissolution medium 
[1% (v/v) of Tween 80 in 10mM HEPES buffer, pH 
7.4] at 37°C. Then at pre-determined time intervals 
of 1, 2 and 3 months the amount of released AmB 
was determined using HPLC method (7). 
Determination of yield and entrapment efficiency
The respective percentage of yield was calculated 
using the following equation:
Percentage of yield=
Weight of nanosphere obtained 
×100
Total weight of AmB 
and polymers used
For determination of  entrapment  efficiency,  the 
content of AmB in loaded nanospheres was 
determined by HPLC as described previously (7). 
Then, the percentage of drug entrapped was 
calculated as:
Percentage of AMB 
entrapment  =
Amount of AmB in particle × 
Total tested volume ×100
Total sample volume × Initial 
amount of AmB
Particle size and zeta-potential measurement
Mean particle size and zeta-potential of the prepared 
nanospheres before and after drying process were 
evaluated by the reported  method using Malvern 
zetasizer (Malvern instrument Ltd., Worcestershire, 
UK) apparatus (14, 15). 
In vitro toxicity
In vitro toxicity of the free and prepared nanospheres 
containing AmB was determined by the reported 
method (16). Briefly, blood samples were collected 
from rabbits in the presence of the heparin. Then, 
0.2 ml of PBS containing various amounts of free 
and  nanosphere  forms  of AmB  (0-400  μg AmB/
ml) were mixed with 0.8 ml of 0.1% red blood 
cells (vol. /vol.) suspension and in vitro haemolytic 
effects of the dose levels of AmB was determined by 
spectrophotometer (model 1700, shimadzu, Japan). 
Antifungal susceptibility testing
The MICs of AmB in free and nanospheres 
loaded forms were determined by microdilution 
methodology, according to Clinical and Laboratory 
Standards Institute (17). Briefly, Candida albicans 
(ATCC 90028) cell suspensions of ~1×106 cells/ml 
were diluted 1:50 in RPMI- 1640 growth medium and 
dispensed (100 μl) into a microtiter tray containing 
serial two-fold dilutions of AmB. The tray was then 
incubated for 48 hrs at 37°C. The MIC was recorded 
to be the lowest concentration of the AmB in free and 
nanosphere forms that prevented visible growth of C. 
albicans and expressed in µg/ml. 
 
In vivo study
In vivo  therapeutic  efficacy  of  the  prepared 
nanoparticles was tested by a described method (16),  
with some modification. Forty male white rabbits 
(2.5-3 kg body weight) obtained from the National 
Institute of Pasture (Iran) were handled according 
to the national guidelines of the laboratory animals 
(18). Animals were infected with 0.25 ml of Candida 
albicans cell suspension (7×106 cells/ml) in normal 
saline via the caudal vein and divided into 4 groups. 
All groups received the drug intravenously as 
follows: Group 1 received free AmB (1mg/kg); groups 
2 received AmB-loaded nanospheres (1 mg/kg); group 
3 received empty nanospheres (1mg/kg) and group 
4 received physiological saline (1ml/kg). All groups 
were treated as described above for 12 days starting 
from the 3rd day of infection. Two days after the 
last dose the survived rabbits were anesthetized 
and sacrificed. Then fungal colony forming units 
(CFU) in lung, liver, kidney, spleen and brain was 
determined.
Statistical analyses
All data were expressed as mean ± S.E.M. The 
CFU values were statistically evaluated by analysis 
of variance of one-way classification with unequal 
frequencies from three separate experiments. The 
percentage of survival rabbits were determined by 
using Chi-squared with Yates correction and by 
Fisher’s exact test.
RESULTS AND DISCUSSION
Yield and Entrapment Efficiency
The results showed that percentage of yield and Gharib et al / DARU 2011 19 (5) 351-355 353
AmB entrapment efficiency were 57.9% ± 8 and 
65.2% ± 3, respectively.
Particle size and zeta-potential analysis
Table 1, shows mean particle size and zeta-potential 
of empty and AmB-loaded nanospheres before and 
after drying process. Size homogeneity of empty 
and AmB-loaded nanospheres which was suggested 
that AmB was entrapped into nanoparticle core, 
according to the previous studies (5, 6). Also, 
the high negative zeta-potential of the prepared 
nanospheres revealed that the nanoparticles have 
appropriate stability in aqueous dispersion (14).
In vitro dissolution studies
The percentage of AmB recoveries for nanospheres 
after 3 months was 90% ± 2 (Fig. 1). This 
phenomenon suggested that majority of AmB 
incorporated into nanoparticles. This result is not 
in accordance with the previous reports that have 
indicated within 5-30 minutes most of AmB were 
released from nanoparticles, because AmB was 
attached to the outer surface of the nanoparticles 
(3, 14). 
In vitro toxicity study
The hemolytic ability of free AmB and AmB-
loaded  nanospheres  is  shown  in  figure  2.  The 
maximum hemolytic result (100% lysis) for AmB-
loaded nanospheres was estimated to be 361 μg/
ml. Under all conditions, by increasing AmB doses 
(0-250 μg AmB/ml), the percentage of haemolytic 
effect increased. AmB-loaded nanospheres showed 
mild toxicity (1.2% lysis of erythrocytes) at 
concentration of 38 μg/ml as compared to the free 
drug. Data of this study are in accordance with 
results of another report (3).
Fungal susceptibilities 
The MIC of AmB-loaded nanospheres against C. 
albicans was reduced 3-fold compared with free 
AmB Table.2. This result indicates that prepared 
AmB-loaded nanospheres like NS-718, LNS-AmB 
and LNPS-AmB (lipid nanoparticles incorporated 
Formulations Mean particle size (nm) zeta-potential (mV)
Before spray-drying
Empty nanospheres 110±2 -33.6±5
AmB-loaded nanospheres 118±5 -31.1±7
After spray-drying
Empty nanospheres 92±3 -29.3±2
AmB-loaded nanospheres 96±1 -27.9±4
Table 1. Particle size and zeta-potential of the empty and AmB-loaded nanospheres before and after spray-drying.
                                                                 Minimum Inhibitory Concentration (MIC,µg/ml)
 Drugs Free AmB AmB-loaded nanospheres    
Microorganism 
Candida albicans (ATCC 90028) 0.5 0.125                     
Table 2. In vitro antifungal activities of AmB in either free or nanosphere forms against Candida albicans (ATCC 90028).
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Figure 1: Percentage of AmB recovery from nanospheres 
prepared with PLGA after 3 months of storage at 37°C.
Figure 2: Percentage of haemolysis with AmB in free and 
entrapment in nanosphere forms. The data was expressed as   
mean ± S.E.M. from three separate experiments.
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Treatment Tissue/Organ
Log CFU
Gram tissue
(n=3)
Percentage of survival  15 day 
after  the therapy (n=10)
Control without drug administration
(received physiological saline)
Lung
Liver
Kidney
Spleen
Brain
4.312 ± 0.5
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4.742 ± 1.3
4.221 ± 1.6
None survived
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None survived
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(1 mg Kg-1, I.V.)
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3.510 ± 0.20
20
AmB-loaded nanospheres
(1 mg Kg-1, I.V.)
Lung
Liver
Kidney
Spleen
Brain
1.193 ± 0.04 *
1.189 ± 0.03 *
Nil **
Nil **
1.116 ± 0.03 *
90
 The values are expressed as mean ± S.E.M. from three separate experiments. Analysis of variance of one-way classification between the
.treatment means was heterogeneous and the t-test values (two-tailed) were significant, * p < 0.05 and ** p <0.001
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